|Description||C086 inhibits Hsp90 and BCR-ABL, resulting in decreased proliferation of tumor cells, including imatinib-resistant cells.|
|Brife Description||C086 inhibits Hsp90 and BCR-ABL, resulting in decreased proliferation of tumor cells, including imatinib-resistant cells.|
|Synonyms||C086; C 086; C-086|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
SNX-2112 is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGF...
TAS-116 is a inhibitor of Hsp90. It induces significant cytotoxicity in MM cells even in the presence of BMSCs, associates with downregulation of phospho-Akt an...
Pochocin D is a patent Hsp90 inhibitor. IC50 80.0nM.
Hsp980 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp980 binds to and inhibits the acti...
VER-50589 is a potent Hsp90 inhibitor with IC50 of 21 nM for Hsp90β.
WK88-1 inhibits Hsp90, resulting in decreased expression of Hsp90 client proteins and potentially leading to decreased tumor cell growth.
Alvespimycin hydrochloride is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds...
VER-49009 is a pyrazole compound inhibitor of Hsp90, IC50 47 nM. It produces a cellular antiproliferative GI50 value of 685 nM when tested against a human cance...